bims-carter 2025-07-27 papers

Issue of 2025–07–27
two papers selected by
Luca Bolliger, lxBio

Autoimmun Rev. 2025 Jul 16. pii: S1568-9972(25)00143-0. [Epub ahead of print]24(10): 103883

The role of γδ T cells and CAR-γδ T cell therapy in autoimmune diseases.

Tengyue Wang, Hongli Wang, Rui Lv, Chengping Wen, Mingzhu Wang, Lin Huang.

Autoimmune diseases represent a major global health challenge, imposing substantial economic, social, and personal burdens on human society. γδ T lymphocytes are a unique T cell subset that bridges innate and adaptive immunity, demonstrating remarkable characteristics in immune regulation and inflammatory modulation. In this context, Chimeric Antigen Receptor (CAR)-γδ T cell therapy emerges as a promising immunotherapeutic strategy with transformative potential in addressing autoimmune disorders. This review comprehensively explores the multifaceted roles of γδ T lymphocytes in autoimmune pathogenesis, highlighting their distinctive functions and properties. It discusses the potential and advantages of applying γδ T cells to CAR-T cell therapy, elucidating the prospects of treating autoimmune diseases through CAR-γδ T cell therapy in the future.

Keywords: Autoimmune diseases; CAR-γδ T cell therapy; Function; Origin; γδ T cells

DOI: https://doi.org/10.1016/j.autrev.2025.103883

Cancer Immunol Immunother. 2025 Jul 24. 74(9): 275

Precision sniper for solid tumors: CAR-NK cell therapy.

Sisi Li, Jiajie Jing, Yueming Chen, Enjie Chi, Bingyan Wang, Ziwen Xie, Wenya Yang, Hongqiang Shen, Jianping Pan.

Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies. However, its efficacy against solid tumors remains inadequate and is accompanied by toxic side effects, including cytokine release syndrome, neurotoxicity and on-target/off-tumor effects. In contrast to T cells, natural killer (NK) cells exhibit a broader source range and can non-specifically lyse tumor cells. Moreover, it can also reduce toxicity and side effects to some extent. This review comprehensively examines recent research progress on CAR-NK therapy for solid tumors, encompassing both in vivo and in vitro studies, with a focus on CAR-NK cell design and production methods. Drawing upon laboratory and clinical evidence, this review summarizes the current challenges and side effects associated with CAR-NK technology.

Keywords: CAR-NK; Immunotherapy; Solid tumors; Targeted therapy

DOI: https://doi.org/10.1007/s00262-025-04106-z